Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 142 participants.

Also called NCT06959784

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 142 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06959784
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06959784. Randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
Condition
Diabetes Mellitus
Condition
Cardiovascular Diseases
Condition
Cerebrovascular Disease
Intervention (Drug)
semaglutide
Intervention (Drug)
Metformin
Lead sponsor
China-Japan Friendship Hospital (class: other)

Record details

Record id
cardio:ct-nct06959784
Content hash
568cc148a5636eb8b53dd4ce1bcdef9146b721608f1bb6abbea079c9c0aa69e6